Show simple item record

dc.contributor.authorWander, P.
dc.contributor.authorCheung, Laurence
dc.contributor.authorPinhanҫos, S.S.
dc.contributor.authorJones, L.
dc.contributor.authorKerstjens, M.
dc.contributor.authorArentsen-Peters, S.T.C.J.M.
dc.contributor.authorSingh, S.
dc.contributor.authorChua, G.A.
dc.contributor.authorCastro, P.G.
dc.contributor.authorSchneider, P.
dc.contributor.authorDolman, M.E.M.
dc.contributor.authorKoopmans, B.
dc.contributor.authorMolenaar, J.J.
dc.contributor.authorPieters, R.
dc.contributor.authorZwaan, C.M.
dc.contributor.authorKotecha, Rishi
dc.contributor.authorStam, R.W.
dc.identifier.citationWander, P. and Cheung, L.C. and Pinhanҫos, S.S. and Jones, L. and Kerstjens, M. and Arentsen-Peters, S.T.C.J.M. and Singh, S. et al. 2020. Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia. Leukemia.

The treatment of children diagnosed with acute lymphoblastic leukemia (ALL) has improved significantly over recent decades, with 5-year event-free survival (EFS) approaching 85% [1]. However, 5-year EFS for infants diagnosed at less than 1 year of age with MLL-rearranged ALL remains less than 40% [2]. MLL-rearranged infant ALL is both clinically and biologically distinct from other childhood ALL subtypes, which is reflected by a unique gene expression profile [3], a remarkably silent mutational landscape [4], and pronounced resistance to currently applied chemotherapeutics [5].

dc.titlePreclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia
dc.typeJournal Article
curtin.departmentSchool of Pharmacy and Biomedical Sciences
curtin.accessStatusFulltext not available
curtin.facultyFaculty of Health Sciences
curtin.contributor.orcidKotecha, Rishi [0000-0003-1836-4075]
curtin.contributor.orcidCheung, Laurence [0000-0001-6298-5288]
curtin.contributor.scopusauthoridCheung, Laurence [56663936300]

Files in this item


This item appears in the following Collection(s)

Show simple item record